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FLT3 modeled structure Phosphorylase B Kinase (PDB ID: 2V7J) Sunitinib Figure S1 . 3D structure alignment of the homology-modeled DFG-in FLT3 structure to the X-ray structure of phosphorylase B kinase (PDB ID: 2Y7J) bound to the ligand sunitinib. Figure S2 . Assessment of the DFG-in FLT3-modeled structure by ERRAT server. The arrows represent the active site residues in the protein model. The overall quality factor of the modeled structure improved after MD simulation. Figure S3 . Assessment of the DFG-in FLT3-modeled structure by Profile-3D server. The arrowed regions represent the active site residues in the protein model. The Verify score improved after MD simulation of the modeled structure. Figure S4 . Ramachandran plot of the homology modeled DFG-in FLT3 structure after MD simulation. 
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D835
Hinge
Gate region
Binding site Figure S5 . FLT3 (DFG-in) ITD insert site and D835 mutation location. Tyrosine kinase domain-1 (TK1, blue color); juxtamembranne domain (JM, red color) and ligand binding site (blue transparent surface). Figure S6 . The IC50 determination dose-reponse curve of BPR056 and BPR080, along with sorafenib. Figure S8 . Aligned structures of the original ligand conformation (green) present in 2Y7J and the docked ligand conformation (gray) of sunitinib in 2Y7J crystal structure. RMSD = 1.50Å, calculation done using Discovery studio 2.1. 
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